November 23rd 2024
FDA's approval will allow Kedrion to manufacture Ryplazim (plasminogen, human-tvmh), the only FDA-approved therapy for treating PLGD-1, at facility in Bolognana, Italy.
November 19th 2024
It is important to understand the differences between risk-based decision making and other decision making in a pharmaceutical quality system.
Ongoing Analytical Procedure Performance Verification—Stage 3 of USP<1220>
Analytical procedure performance can be continually verified by risk-based monitoring of performance related data.